Background/Aim: We employed a multimodal evaluation of voice outcome (MEVO) model to assess long-term voice outcome in early glottic cancer (EGC) patients treated with primary radiotherapy (RT). The model consisted of objective and subjective vocal evaluation during follow-up, by a dedicated Speech Pathologist and Speech Therapist. Patients and Methods: MEVO methodology includes Self-perception Voice Handicap Index (VHI-30), evaluation of parameters Grade (G), Roughness (R), Breathiness (B), Asthenia (A) and Strain (S) according to GRBAS scale, objective analysis and aerodynamics using the PRAAT software and laryngeal evaluation with videostroboscope (VS). Results: The MEVO methodology was described and tested on a sample of 10 EGCs submitted to definitive RT (total dose 66-70 Gy). Mean follow-up was 48.9 months (range=9-115). VHI was mild-moderate in 90% of patients; overall voice function (GRBAS) was normal-mildly impaired in 70% of patients; VS evaluation showed normal vocal cord motion in 90% of patients, but complete glottic closure in 60%. PRAAT scores confirmed these findings. Conclusion: A multidimensional voice evaluation is time consuming, but useful to objectify vocal impact of radiotherapy. The MEVO model allowed to quantify vocal dysfunction, showing a good objective vocal outcome. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: We employed a multimodal evaluation of voice outcome (MEVO) model to assess long-term voice outcome in early glottic cancer (EGC) patients treated with primary radiotherapy (RT). The model consisted of objective and subjective vocal evaluation during follow-up, by a dedicated Speech Pathologist and Speech Therapist. Patients and Methods: MEVO methodology includes Self-perception Voice Handicap Index (VHI-30), evaluation of parameters Grade (G), Roughness (R), Breathiness (B), Asthenia (A) and Strain (S) according to GRBAS scale, objective analysis and aerodynamics using the PRAAT software and laryngeal evaluation with videostroboscope (VS). Results: The MEVO methodology was described and tested on a sample of 10 EGCs submitted to definitive RT (total dose 66-70 Gy). Mean follow-up was 48.9 months (range=9-115). VHI was mild-moderate in 90% of patients; overall voice function (GRBAS) was normal-mildly impaired in 70% of patients; VS evaluation showed normal vocal cord motion in 90% of patients, but complete glottic closure in 60%. PRAAT scores confirmed these findings. Conclusion: A multidimensional voice evaluation is time consuming, but useful to objectify vocal impact of radiotherapy. The MEVO model allowed to quantify vocal dysfunction, showing a good objective vocal outcome. Copyright 2021, International Institute of Anticancer Research.
Authors: P H Dejonckere; P Bradley; P Clemente; G Cornut; L Crevier-Buchman; G Friedrich; P Van De Heyning; M Remacle; V Woisard Journal: Eur Arch Otorhinolaryngol Date: 2001-02 Impact factor: 2.503
Authors: Matthew T Greulich; Noah P Parker; Philip Lee; Albert L Merati; Stephanie Misono Journal: Otolaryngol Head Neck Surg Date: 2015-04-02 Impact factor: 3.497
Authors: A Ferlito; A Carbone; A Rinaldo; A Ferlito; L W DeSanto; L D'Angelo; L Barnes; K O Devaney Journal: Ann Otol Rhinol Laryngol Date: 1996-03 Impact factor: 1.547
Authors: Laura Warner; Jessal Chudasama; Charles G Kelly; Sean Loughran; Kenneth McKenzie; Richard Wight; Paola Dey Journal: Cochrane Database Syst Rev Date: 2014-12-12
Authors: Elisabeth V Sjögren; Maya A van Rossum; Ton P M Langeveld; Marika S Voerman; Vivienne A H van de Kamp; Mark O W Friebel; Ron Wolterbeek; Robert J Baatenburg de Jong Journal: Arch Otolaryngol Head Neck Surg Date: 2008-09